• Explore /
  • Poster
  • / Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC).

Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC).

Abstract Poster

Authors

null

A. M. Gonzalez-Angulo

M. D. Anderson Cancer Center, Houston, TX

A. M. Gonzalez-Angulo , M. C. Green , J. L. Murray , S. L. Palla , K. H. Koenig , A. M. Brewster , V. Valero , N. K. Ibrahim , S. L. Moulder , J. K. Litton , D. J. Crawford , P. R. Flores , M. J. Dryden , W. F. Symmans , S. H. Giordano , L. Pusztai , A. Buzdar , G. B. Mills , G. N. Hortobagyi , F. Meric-Bernstam

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer - Triple-negative/Cytotoxics/Local Therapy

Track

Breast Cancer

Sub Track

Triple-Negative Breast Cancer

Clinical Trial Registration Number

NCT00499603

Citation

J Clin Oncol 29: 2011 (suppl; abstr 1016)

Abstract #

1016

Poster Bd #

6

Abstract Disclosures

Similar Posters

First Author: Naoko Matsuda

First Author: Kenji Higaki

First Author: David B. Page

First Author: Sherene Loi